Lemaitre Vascular, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Petusky from Barrington maintained a Buy rating on the stock and has a $95.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Petusky’s rating is based on several positive indicators for Lemaitre Vascular. The company has demonstrated strong pricing power, with a significant portion of its organic growth attributed to price increases, and this trend is expected to continue into 2026. Additionally, Lemaitre has made substantial progress in achieving MDR compliance in the EU, which positions it well for market share gains as competitors struggle with compliance costs.
Moreover, Lemaitre’s financial position is robust, with substantial cash reserves that could be used for strategic acquisitions, enhancing its growth prospects. The recent commercial launch of XenoSure in China and potential regulatory approvals for other products also present future growth opportunities. These factors collectively support the Buy rating, with a price target of $95 based on projected financial performance.
According to TipRanks, Petusky is a 2-star analyst with an average return of 0.3% and a 43.48% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Option Care Health, Haemonetics, and Lifecore Biomedical.